Scarica l'app Stockscreener
6.25
0.95%
-0.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché WVE Giù?
Forum
Previsione
Precedente Chiudi:
$6.31
Aprire:
$6.36
Volume 24 ore:
3.45M
Relative Volume:
0.93
Capitalizzazione di mercato:
$1.20B
Reddito:
$71.80M
Utile/perdita netta:
$-183.59M
Rapporto P/E:
-5.9281
EPS:
-1.0543
Flusso di cassa netto:
$-186.52M
1 W Prestazione:
-0.16%
1M Prestazione:
+10.42%
6M Prestazione:
-54.84%
1 anno Prestazione:
-21.38%
Intervallo 1D:
$5.755
$6.36
Intervallo di 1 settimana:
$5.755
$6.48
Portata 52W:
$5.02
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Nome
Wave Life Sciences Ltd
Settore
Industria
Telefono
617-949-2900
Indirizzo
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
6.25 | 1.20B | 71.80M | -183.59M | -186.52M | -1.0543 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-05 | Iniziato | BofA Securities | Buy |
| 2025-12-12 | Reiterato | Wedbush | Outperform |
| 2025-12-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-04 | Iniziato | Canaccord Genuity | Buy |
| 2025-07-28 | Iniziato | Oppenheimer | Outperform |
| 2025-07-16 | Iniziato | Citigroup | Buy |
| 2025-06-11 | Ripresa | Raymond James | Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Iniziato | Wedbush | Outperform |
| 2025-02-25 | Iniziato | Jefferies | Buy |
| 2024-10-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | Ripresa | JP Morgan | Overweight |
| 2024-09-19 | Iniziato | B. Riley Securities | Buy |
| 2024-09-09 | Iniziato | JP Morgan | Overweight |
| 2024-05-15 | Iniziato | Wells Fargo | Overweight |
| 2023-12-19 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Iniziato | Raymond James | Outperform |
| 2023-05-24 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | Iniziato | Guggenheim | Buy |
| 2019-07-15 | Iniziato | Cowen | Market Perform |
| 2019-04-17 | Reiterato | H.C. Wainwright | Buy |
| 2018-08-07 | Iniziato | Stifel | Buy |
| 2018-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-19 | Reiterato | Mizuho | Buy |
| 2017-02-15 | Iniziato | H.C. Wainwright | Buy |
| 2016-11-10 | Ripresa | Leerink Partners | Outperform |
| 2015-12-07 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-07 | Iniziato | Jefferies | Buy |
| 2015-12-07 | Iniziato | Leerink Partners | Outperform |
| 2015-12-07 | Iniziato | Sun Trust Rbsn Humphrey | Buy |
Mostra tutto
Wave Life Sciences Ltd Borsa (WVE) Ultime notizie
WVE Technical Analysis & Stock Price Forecast - Intellectia AI
ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It? - Stocktwits
Has Wave Life Sciences (WVE) Fallen Far Enough To Look Fairly Valued? - simplywall.st
Wave Life Sciences (WVE) Jefferies London Healthcare Conference 2025 Summary - Quartr
Wave Life Sciences court hearing set for July 14 on redomiciliation - Investing.com
Wave Life Sciences court hearing set for July 14 on redomiciliation By Investing.com - Investing.com South Africa
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation - The Manila Times
What Went Wrong For WVE? The Obesity Drug Trial Data That Spooked Investors - Stocktwits
Wave Life Sciences (WVE) Is Up 7.4% After Advancing RNA-Based Obesity Drug Into Phase 2a Trial - simplywall.st
Is Wave Life Sciences (WVE) Undervalued On Its New Obesity Trial Progress? - simplywall.st
Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect? - Yahoo Finance
Jessica Chen - White & Case LLP
(WVE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Wave Life Sciences (WVE) Initiates Multidose Phase 2a for INLIGHTTM Trial - Insider Monkey
Price to earnings forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView
7 Singapore Companies That Have Listed On Nasdaq And Where They Are Now - DollarsAndSense.sg
Does Wave Life Sciences’ (WVE) RNA Obesity Program Signal a Shift in Its Competitive Positioning? - simplywall.st
Enterprise value to EBITDA forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView
Price to sales forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView
Enterprise value to EBIT forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView
Price to book forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView
Price to book forward of Wave Life Sciences Ltd. – DUS:1U5 - TradingView
Wave Life Sciences (WVE) shareholders approve Singapore Scheme for redomiciliation - Stock Titan
We Think Wave Life Sciences (NASDAQ:WVE) Can Afford To Drive Business Growth - Moomoo
Price to earnings forward of Wave Life Sciences Ltd. – DUS:1U5 - TradingView
Wave Life Sciences(WVE) Stock Options Chain | Quotes & News - Moomoo
Wave Life Sciences Ltd. Actuals & Estimates (NASDAQ:WVE) - TradingView
WVE Forecast — Price Target — Prediction for 2027 - TradingView
Wave Life Sciences initiates phase 2a obesity trial for WVE-007 By Investing.com - Investing.com Australia
Wave Life Sciences initiates phase 2a obesity trial for WVE-007 - Investing.com UK
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT Trial of WVE-007 for Obesity and Cardiometabolic Diseases - Investing News Network
Wave Life Sciences Ltd. (WVE) stock price, news, quote and history - Yahoo Finance Australia
Wave Life Sciences (WVE) Advances Phase 2a Clinical Trial for WV - GuruFocus
Wave Life Sciences Starts Phase 2 Trial of Obesity Drug - Moomoo
Wave Life Sciences Initiates Phase 2a of INLIGHT Trial of WVE-007 for Obesity, Reporting Sustained Visceral Fat Reduction in Phase 1 Data - Quiver Quantitative
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases - The Manila Times
Wave Life Sciences Announces Initiation of Phase 2a Portion - GlobeNewswire
Price-Driven Insight from (WVE) for Rule-Based Strategy - Stock Traders Daily
The Bull Case For Wave Life Sciences (WVE) Could Change Following A Zacks Earnings-Estimate Upgrade - simplywall.st
WAVE LIFE SCIENCES LTD (WVE) Stock Chart - ChartMill
WAVE Life Sciences Ltd (WVE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
WAVE Life Sciences Ltd (WVE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
WAVE Life Sciences Ltd (WVE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
WAVE Life Sciences Ltd (WVE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
WAVE Life Sciences Ltd (WVE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
WAVE Life Sciences Ltd (WVE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Wave Life Sciences (WVE) Stock Could Be 73% Undervalued After WVE 006 Data - simplywall.st
Wave Life Sciences (WVE) Upgraded to Buy: Here's Why - Yahoo Finance
Wave Life Sciences Ltd Azioni (WVE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Wave Life Sciences Ltd Azioni (WVE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 27 '26 |
Buy |
6.43 |
2,495,623 |
16,046,856 |
26,004,414 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 30 '26 |
Buy |
6.50 |
971,091 |
6,312,092 |
26,975,505 |
| Francis Chris | See Remarks |
Feb 26 '26 |
Option Exercise |
4.28 |
33,194 |
141,920 |
79,767 |
| Francis Chris | See Remarks |
Feb 26 '26 |
Sale |
15.05 |
33,194 |
499,593 |
61,867 |
| Moran Kyle | Chief Financial Officer |
Feb 09 '26 |
Sale |
13.45 |
3,588 |
48,259 |
134,385 |
| BOLNO PAUL | President and CEO |
Feb 09 '26 |
Sale |
13.45 |
10,480 |
140,956 |
275,520 |
| Francis Chris | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
1,883 |
25,326 |
61,867 |
| Vargeese Chandra | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
3,228 |
43,417 |
408,246 |
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):